Kromek Group plc
Kromek Group plc is a UK-headquartered (County Durham) developer and manufacturer of radiation detection and bio-detection technology, based on proprietary cadmium zinc telluride (CZT) and associated material science. It operates two reporting segments: Advanced Imaging (CT/SPECT medical imaging detector components, security and industrial screening) and CBRN Detection (nuclear, radiological, chemical and biological-threat detection for government/defence customers). It has manufacturing operations in the UK and US and sells into 40+ countries.
FY2026 in sixty seconds
year to 30 Apr 2026 · approved 11 Sept 2026 · 106 pages · Company website
Kromek Group plc makes detectors that spot radiation and biological threats, used in medical scanners, security screening and defence. In the year to 30 April 2026 its revenue rose 2.3% to £27.1m. Profit after tax fell to £733k, from £3.8m the year before.
The main reason was less income from a highly profitable licensing deal with Siemens Healthineers, which brought in £10.0m of revenue against £16.5m a year earlier. Sales were also helped by a one-off large order from an existing imaging customer. The defence and security detection business grew. Lower costs, including smaller charges for unpaid bills and fewer one-off fees tied to the Siemens deal, softened the fall in profit.
Cash at the year end was £4.2m, up from £1.7m, but borrowings rose to £5.7m, so the company owed more than it held. Almost no new money was raised from shareholders, and no dividend was paid. Management expects revenue to grow for a sixth year running and "significant underlying growth" in the year ahead. The auditor raised no doubt about the company's ability to keep going.
Enablement/Patent Licensing Agreement with Siemens Healthineers (Siemens Medical Solutions USA Inc.) for CZT SPECT detector production, total $37.5m over four years
Revenue recognised in year relating to the Enablement Agreement was £10.0m (2025: £16.5m); to date the Company has received $32.5m of the $37.5m total, with $5.0m remaining payable on completion of final milestone expected FY2029
page 15Enablement Agreement licensing revenue mix
Gross margin fell to 62.8% (2025: 80.9%) due to revenue mix, including high-margin licensing revenue accounting for a higher proportion of revenue in 2025 vs 2026; management expects margins to return to mid-50s in FY2027 as this reverts to the historical underlying level
page 4I am excited about Kromek's future, we anticipate delivering revenue growth for the sixth consecutive year and profit generation for the third consecutive year (Chairman)
page 9The Directors do not recommend the payment of a dividend for the year ended 30 April 2026 (2025: £nil)
page 3612 years on one page · FY2015–FY2026
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY2023locked | FY202404/24 | FY202504/25 | FY202604/26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Operating profit | ||||||||||||
| Profit for the year | ||||||||||||
| Basic EPS | ||||||||||||
| Dividend per share | — | |||||||||||
| Free cash flow | ||||||||||||
| Net debt (negative = net cash) | ||||||||||||
| Shares in issue | ||||||||||||
| Operating margin | ||||||||||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
4 figures restated in a later report
Every figure is read again from the following year’s report: 422 confirmed, 1 differ, 4 restated.
No figure has been restated: every figure a later report printed again, it printed the same.
4 more figures were restated in FY2015 to FY2023, which a free account opens.